Neuland Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Davuluri Rama Mohan Rao, a promoter of Neuland Laboratories, has submitted a declaration under SEBI's Regulation 31(4) of the Takeover Regulations. He confirms that the promoter and promoter group have not created any new encumbrance (pledge, charge, or lien) on the company's shares during FY 2024-25, other than any previously disclosed. This is a routine annual compliance filing required from promoters each financial year. The declaration is addressed to BSE, NSE, and the company's Audit Committee.
This is a neutral, routine compliance filing. It reassures shareholders that promoters have not pledged or encumbered additional shares, which is mildly positive as it means no new financial stress signals from the promoter group.